主要作者 | 摘要标题 | 报告详情(CEST) |
抗体偶联药物 |
Harbeck, N | DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan
alone (T-DXd) or followed by paclitaxel + trastuzumab +
pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+
early breast cancer (eBC) | Abstract #291O Presidential 1 18 October 2025 4:30 PM |
Geyer, C | Trastuzumab deruxtecan (T-DXd) vs trastuzumab
emtansine (T-DM1) in patients (pts) with high-risk human
epidermal growth factor receptor 2–positive (HER2+)
primary breast cancer (BC) with residual invasive disease
after neoadjuvant therapy (tx): Interim analysis of
DESTINY-Breast05 | Abstract #LBA1 Presidential 1 18 October 2025 4:52 PM |
Dent, R. | First-line (1L) datopotamab deruxtecan (Dato-DXd) vs
chemotherapy in patients with locally recurrent inoperable
or metastatic triple-negative breast cancer (mTNBC) for
whom immunotherapy was not an option: Primary results
from the randomised, phase 3 TROPION-Breast02 trial | Abstract #LBA21 Proffered Paper Session 19 October 2025 9:25 AM |
Loibl, S | Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane
+ trastuzumab + pertuzumab (THP) for patients with
HER2+ advanced/metastatic breast cancer: additional
analysis of DESTINY-Breast09 in key subgroups of interest | Abstract #LBA18 Proffered Paper Session 19 October 2025 8:30 AM |
Rha, SY | Datopotamab deruxtecan (Dato-DXd) + rilvegostomig
(rilve) in patients (pts) with locally advanced or metastatic
urothelial cancer (a/mUC): Results from the phase 2
TROPION-PanTumor03 study | Abstract #3072MO Mini Oral Session 17 October 2025 4:10 PM |
Oaknin, A | First-in-human study of AZD5335, a folate receptor α
(FRα)-targeted antibody-drug conjugate, in patients with
platinum-resistant recurrent ovarian cancer | Abstract #1065MO Mini Oral Session 19 October 2025 10:53 AM |
Schmid, P | Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as
first-line (1L) treatment (tx) for unresectable locally
advanced/metastatic triple-negative breast cancer
(a/mTNBC): Final results from the phase 1b/2 BEGONIA
study | Abstract #555MO Mini Oral Session 20 October 2025 10:50 AM |
Raghav, K | Trastuzumab deruxtecan (T DXd) in patients (pts) with
HER2-positive (HER2+) metastatic colorectal cancer
(mCRC): Final analysis of DESTINY-CRC02, a
randomized, phase 2 trial | Abstract #737P Poster Session |
Peng, Z | Trastuzumab deruxtecan (T-DXd) in patients (pts) with
HER2+ gastric cancer (GC) or gastroesophageal junction
adenocarcinoma (GEJA) who received prior anti-HER2
treatment (Tx) other than / in addition to trastuzumab in
DESTINY-Gastric06 (DG-06) | Abstract #2105P Poster Session |
Shen, L | Risk of hepatitis B virus reactivation (HBVr) in patients
(pts) with past or resolved HBV or inactive chronic HBV
infection treated with trastuzumab deruxtecan (T-DXd) in
the DESTINY-Gastric06 (DG-06) trial | Abstract #2175P Poster Session |
Pietrantonio, F | Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM)
plus paclitaxel (PTX) in second-line (2L) treatment of
patients (pts) with HER2+ unresectable/metastatic gastric
cancer (GC)/gastroesophageal junction adenocarcinoma
(GEJA): Additional data from DESTINY-Gastric04 (DG-04) | Abstract #2099P Poster Session |
Makker, V | Trastuzumab deruxtecan (T-DXd) for pretreated patients
(pts) with HER2-expressing solid tumors: DESTINY-
PanTumor02 (DP-02) Part 1 final analysis | Abstract #957P Poster Session |
Lee, J-Y | Trastuzumab deruxtecan (T-DXd) in pretreated patients
(pts) with HER2-expressing solid tumors: exploratory
biomarker analysis of DESTINY-PanTumor02 (DP-02) Part
1 | Abstract #145P Poster Session |
免疫肿瘤学 |
Tabernero, J | MATTERHORN Phase III trial of Imfinzi (durvalumab)
perioperative Imfinzi (durvalumab) plus FLOT
chemotherapy in patients with resectable, early-stage and
locally advanced gastric and gastroesophageal junction
(GEJ) cancers | Abstract #LBA81 Proffered Paper Session 17 October 2025 2:00 PM |
De Santis, M | Durvalumab (D) in Combination with Bacillus Calmette-
Guérin (BCG) for BCG-naïve, High-risk Non-muscle-
invasive Bladder Cancer (NMIBC): Results from the Phase
3, Open-label, Randomised POTOMAC Trial | Abstract #LBA108 Proffered Paper Session 17 October 2025 2:10 PM |
Larkin, J | First results from RAMPART: An international phase 3
randomised-controlled trial of adjuvant durvalumab
monotherapy or combined with tremelimumab for resected
primary renal cell carcinoma (RCC) led by MRC CTU at
UCL | Abstract #LBA93 Proffered Paper Session 18 October 2025 9:20 AM |
Aghajanian, C | Durvalumab + paclitaxel/carboplatin + bevacizumab
followed by durvalumab, bevacizumab + olaparib
maintenance in patients with newly diagnosed non-tBRCA-
mutated advanced ovarian cancer: final overall survival
from DUO-O/ENGOT-ov46/GOG-3025 | Abstract #LBA44 Mini Oral Session 19 October 2025 11:31 AM |
Goss, G | CCTG BR.31: Adjuvant durvalumab (D) in resected non-
small-cell lung cancer (NSCLC): final overall survival (OS)
and minimal residual disease (MRD) analyses | Abstract #LBA68 Mini Oral Session 20 October 2025 3:20 PM |
Heymach, J | Association of radiomic features ± on-treatment ctDNA
detection with treatment outcomes in patients with
resectable NSCLC: exploratory analyses from AEGEAN | Abstract #LBA70 Mini Oral Session 20 October 2025 3:50 PM |
Wermke, M | Tarlatamab with first-line chemoimmunotherapy for
extensive stage small cell lung cancer (ES-SCLC):
DeLLphi-303 study | Abstract #2757O Proffered Paper Session 18 October 2025 8:30 AM |
Loibl, S | Durvalumab in Combination with Neoadjuvant
Chemotherapy in Early Triple-Negative Breast Cancer
(TNBC) – Long-term Analysis from the GeparNuevo Trial | Abstract #292MO Mini Oral Session 19 October 2025 10:15 AM |
Van der Heijden, M | Health-related quality of life (HRQoL) from the NIAGARA
trial of perioperative durvalumab (D) plus neoadjuvant
chemotherapy (NAC) in muscle-invasive bladder cancer
(MIBC) | Abstract #3069MO Mini Oral Session 17 October 2025 4:00 PM |
Sangro, B | Pooled efficacy and safety outcomes with tremelimumab
plus durvalumab in participants (pts) with unresectable
hepatocellular carcinoma (uHCC) from the combined
China extension and global cohorts in the Phase 3
HIMALAYA study | Abstract #1494P Poster Session |
Westin, S | Durvalumab plus carboplatin/paclitaxel followed by
durvalumab for endometrial cancer: Tumour mutational
burden-high subpopulation efficacy analyses from the
DUO-E trial | Abstract #1117P Poster Session |
Leal, TA | Global quantitative assessment of multidisciplinary team
(MDT) care in early-stage NSCLC | Abstract #1794P Poster Session |
Reck, M | Neoadjuvant durvalumab (D) + chemotherapy (CT)
followed by either surgery (Sx) and adjuvant D or CRT and
consolidation D in patients (pts) with resectable or
borderline resectable stage IIB–IIIB NSCLC: interim
analysis (IA) of the phase 2 MDT-BRIDGE study | Abstract #LBA65 Proffered Paper Session 18 October 2025 9:15 AM |
Maruki, Y | CELEBRATE Study (JCOG2107E): A Multicenter, Open-
label, Phase III Trial of Etoposide, Carboplatin, and
Durvalumab in First-line Treatment of Unresectable or
Recurrent Digestive NEC | Abstract #1734TiP Poster Session |
Oudard, S | A phase IIIb, open-label, single-arm, global study of
perioperative durvalumab (D) with neoadjuvant dose-
dense methotrexate, vinblastine, doxorubicin, and cisplatin
(ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients
with muscle-invasive bladder cancer (MIBC) (NIAGARA-2) | Abstract #3133eTiP ePoster Session |
双特异性抗体 |
Chul Cho, B | Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT
Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve
Metastatic Non-Small-Cell Lung Cancer (mNSCLC):
ARTEMIDE-01 | Abstract #1853MO Mini Oral Session 20 October 2025 10:25 AM |
Slomovitz, BM | A randomized Phase 3 study of first-line (1L) trastuzumab
deruxtecan (T-DXd) with rilvegostomig or pembrolizumab
in patients with HER2-expressing, mismatch repair-
proficient (pMMR), primary advanced or recurrent
endometrial cancer (EC): DESTINY-Endometrial01/GOG-
3098/ENGOT-EN24 | Abstract #1223TiP Poster Session |
Naidoo, J | ARTEMIDE-Lung04: A Phase 3, randomised, double-blind,
global study of rilvegostomig or pembrolizumab
monotherapy as first-line (1L) treatment for patients with
metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50% | Abstract #2025TiP Poster Session |
肿瘤驱动因子和耐药性 |
Jänne, PA | FLAURA2: exploratory overall survival (OS) analysis in
patients (pts) with poor prognostic factors treated with
osimertinib (osi) ± platinum-pemetrexed chemotherapy
(CTx) as first-line (1L) treatment for EGFR-mutated
(EGFRm) advanced NSCLC | Abstract #LBA77 Proffered Paper Session 17 October 2025 4:56 PM |
Mayer, E | Patient-reported outcomes (PROs) from the SERENA-6
trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i)
for emergent ESR1m during first-line (1L) endocrine-based
therapy and ahead of disease progression in patients (pts)
with HR+/HER2- advanced breast cancer (ABC) | Abstract #486MO Mini Oral Session 20 October 2025 10:25 AM |
Arriola, E | Molecular residual disease (MRD) analysis from the
LAURA study of osimertinib (osi) in unresectable (UR)
stage III EGFR-mutated (EGFRm) NSCLC | Abstract #1817MO Mini Oral Session 20 October 2025 2:55 PM |
Park, YH | Visual symptom questionnaire results from SERENA-6, a
Phase 3 study of switch to camizestrant (CAMI) + CDK4/6
inhibitor (CDK4/6i) at emergence of ESR1m during first-
line (1L) therapy for patients (pts) with HR+/HER2-
advanced breast cancer (ABC) | Abstract #528P Poster Session |
Chu, Q | SAVANNAH: Safety and tolerability of osimertinib (osi) +
savolitinib (savo) in EGFRm advanced NSCLC with MET
overexpression and/or amplification (OverExp/Amp)
following disease progression on osi | Abstract #1955P Poster Session |
Rotow, J | MET testing and treatment (tx) sequencing after
progression on first line (1L) osimertinib (osi) in patients
(pts) with EGFRm advanced NSCLC and acquired MET
overexpression and/or amplification (OverExp/Amp):
Interim analysis of a global real world (rw) study | Abstract #1967P Poster Session |
Yu, Y | ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo)
plus osimertinib (osi) versus chemotherapy (chemo) in
MET-amplified (METamp) advanced NSCLC after disease
progression (PD) on EGFR tyrosine kinase inhibitor (TKI) | Abstract #1954P Poster Session |
DNA损伤应答 |
Azad, AA | First interim efficacy analysis of the Phase 1/2 PETRANHA
trial of saruparib + androgen receptor pathway inhibitors
(ARPI) in patients (pts) with metastatic prostate cancer
(mPC) | Abstract #2384MO Mini Oral Session 17 October 2025 2:35 PM |
Fizazi, K | A Phase 3 study of capivasertib (capi) + abiraterone (abi)
vs placebo (pbo) + abi in patients (pts) with PTEN deficient
de novo metastatic hormone-sensitive prostate cancer
(mHSPC): CAPItello-281 | Abstract #2383O Proffered Paper Session 19 October 2025 11:19 AM |
Rugo, HS | Capivasertib with fulvestrant as first- and second-line
endocrine therapy in PIK3CA/AKT1/PTEN-altered
hormone receptor-positive advanced breast cancer:
Subgroup analysis from the Phase 3 CAPItello-291 trial | Abstract #526P Poster Session |
Gao, Q | Final overall survival (OS) analysis of L-MOCA: olaparib
maintenance monotherapy in patients (pts) with platinum-
sensitive relapsed ovarian cancer (PSR OC) | Abstract #1090P Poster Session |
AI驱动的临床试验 |
Gonuguntla, HK | Real-World Validation of AI-defined Lung Nodule
Malignancy Score (qXR-LNMS) in Predicting Risk of Lung
Cancer: Interim results from Phase 2 | Abstract #2978P Poster Session |
